Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage IVB Lung Cancer AJCC v8: early-phase trial registry
6 of 35 indexed Stage IVB Lung Cancer AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #435 of 28,707 conditions by registered trial count.
35 US clinical trials · 6 currently recruiting · #435 of 28,707 conditions by registered trial count
Stage IVB Lung Cancer AJCC v8: 35 US clinical trials tracked, 6 recruiting.
Stage IVB Lung Cancer AJCC v8 is the subject of 35 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 30 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 9 of these trials.
Enrollment posture brief
Registry condition stage-ivb-lung-cancer-ajcc-v8
OPEN 6 | RECR 17% | LATE 0 | EARLY 30 | RANK #435 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Gliosarcoma (17% recruiting · 35 trials)
Stage IVB Lung Cancer AJCC v8 lists 6 open slots (17% of 35 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage IVB Lung Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage IVB Lung Cancer AJCC v8 is recruiting below its size-band peers.
6 of 35 indexed trials (17.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage IVB Lung Cancer AJCC v8 research.
M.D. Anderson Cancer Center accounts for 9 of 35 trials (25.7%). 12 distinct sponsors appear on at least one study for this condition label.
-
Most Stage IVB Lung Cancer AJCC v8 trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 35 trials that report a genuine target (sentinel values excluded). 30 of those (85.7%) plan for fewer than 100 participants.
-
Stage IVB Lung Cancer AJCC v8 research is mostly interventional.
33 interventional and 2 observational studies make up this index (94.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
35 total, page 1 of 1
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Emory University
NCT04762199
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Dwight Owen
NCT04919382
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Dwight Owen
NCT05234307
Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
Stanford University
NCT03582124
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
NCT04780568
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
Emory University
NCT05493566
A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer
Ohio State University Comprehensive Cancer Center
NCT05215769
Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study
M.D. Anderson Cancer Center
NCT03410043
Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
SWOG Cancer Research Network
NCT04268550
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
NCT04625647
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
NCT04533451
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
NCT05096663
Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial
M.D. Anderson Cancer Center
NCT04728230
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
Jonsson Comprehensive Cancer Center
NCT03830918
Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis
M.D. Anderson Cancer Center
NCT04516070
Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer
Roswell Park Cancer Institute
NCT04073745
A Nurse-Led Intervention for Fear of Progression in Advanced Cancer
City of Hope Medical Center
NCT04819997
Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced
M.D. Anderson Cancer Center
NCT03225664
Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT03707938
Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT05017025
Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
Emory University
NCT04340882
Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
NCT04285671
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy
National Cancer Institute (NCI)
NCT03965689
Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT03637816
CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
NCT03546361
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT04250545
All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Dwight Owen
NCT04919369
Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
National Cancer Institute (NCI)
NCT02589522
Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT04837716
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT03737994
Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer
City of Hope Medical Center
NCT05166616
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC
City of Hope Medical Center
NCT04227028
4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis
M.D. Anderson Cancer Center
NCT00862680
Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer
Thomas Jefferson University
NCT03944265
Evaluating Modifiable Biomarkers for the Prediction of Immunotherapy Response and Toxicity
Ohio State University Comprehensive Cancer Center
NCT04954885
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 19 |
| Phase 2 | 11 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage IVB Lung Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage IVB Lung Cancer AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage IVB Lung Cancer AJCC v8 page
35 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Stage IVB Lung Cancer AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Stage IVB Lung Cancer AJCC v8 trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IVB Lung Cancer AJCC v8 condition card totals 35 registered trials; most-linked intervention Questionnaire Administration; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.